MigShield was created to deliver powerful nutritional support for adults who suffer, and are ready to reclaim their lives. Based on the latest research, MigShield is formulated from three key, high quality ingredients that come together to produce results:
Adults take 1 tablet twice daily or as directed by a doctor. MigShield is formulated to provide benefits within the 4 to 12 week build up period. Continue using once you notice benefits.
Microcrystalline cellulose, croscarmellose sodium, stearic acid, silicon dioxide, magnesium stearate (vegetable source), maltodextrin, sunflower lecithin, palm oil, guar gum.
Does not contain: Yeast, milk, soy, salt, artificial flavorings or preservatives.
Supplement Facts | ||
Serving Size: 1 Tablet | ||
Amount Per Serving | %Daily Value | |
Riboflavin | 200 mg | 15,385% |
Magnesium (as magnesium oxide and magnesium citrate) |
200 mg | 48% |
Coenzyme Q10 (ubiquinone) | 75 mg | |
Daily Value not established. |
Keep out of reach of children. If pregnant or breastfeeding, or if you have a medical condition, or if taking any medications or other supplements, consult a health professional before use.
Safety sealed for your protection.
This product is not formulated to provide immediate pain relief.
While Health Central USA strives to ensure the accuracy of its product images and information, some manufacturing changes to packaging and/or ingredients may be pending update on our site. Although items may occasionally ship with alternate packaging, freshness is always guaranteed. We recommend that you read labels, warnings and directions of all products before use and not rely solely on the information provided by Health Central USA.
Cost: | $25 |
Free Shipping: | We offer free shipping on orders over $30. Please check the free - shipping eligibility at checkout. |
Delivery Time: | It usually takes [3-5] business days for standard shipping. Please note that this is an estimated time frame and may be affected by local holidays, and unforeseen circumstances. |
Reviews
There are no reviews yet.